This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
by Zacks Equity Research
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) reachead $81.01 at the closing of the latest trading day, reflecting a -0.53% change compared to its last close.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Why Biotech ETFs Are Beating the Market
by Neena Mishra
: Biotech stocks are poised to benefit from lower rates
Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for COWZ
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for COWZ
Top Stock Reports for Texas Instruments, Union Pacific & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Union Pacific Corporation (UNP) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Gencor Industries, Inc. (GENC).
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
by Ekta Bagri
Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
by Zacks Equity Research
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?
by Ekta Bagri
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 24.84% and 4.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Continuing Claims Hit Highest Since Nov 2021
by Zacks Equity Research
Continuing Claims Hit Highest Since Nov 2021
Jobless Claims Decline, Pre-Markets in the Green
by Zacks Equity Research
It???s a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week.
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 17.14% and 21.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 52.63% and 156.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Kanishka Das
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.